PROLIFIC – Idiopathic Pulmonary Fibrosis

Celgene, a wholly owned subsidiary of Bristol-Myers Squibb Company, created a consortium called PROLIFIC (Prognostic Lung Fibrosis Consortium). Members include: Biogen, Genentech, Inc., Lung Therapeutics, Inc., OptiKira LLC, Pliant Therapeutics, Inc. and Respivant Sciences GmbH and the Pulmonary Fibrosis Foundation. PROLIFIC looks to identify biomarkers  for use in the development of new therapies for pulmonary fibrosis.

Using published data on potential prognostic markers, PROLIFIC has selected 12 biomarkers to include in their research. These markers are intended to characterize epithelial damage (CYFRA 21-1, SP-D, CA-19-9, KL-6), fibrosis (MMP-7, Tenascin C, Periostin), inflammation (CCL18, CXCL13, slCAM1), and thrombosis (PAI-1).

Myriad RBM is developing optimized versions of the panel of 12 assays to support the clinical trial activities of the PROLIFIC members in the area of  idiopathic pulmonary fibrosis (IPF).

Myriad RBM’s immunoassay development process includes a careful selection and optimization of all reagents, not only the capture and detection antibodies, but also the buffers, diluents and blockers. This enables the sensitive and accurate quantitation of analytes in clinical samples. These processes result in the highest quality assay services and allow for rigorously maintained quality year after year, a requirement to late-stage support clinical trials.


About Myriad RBM

Myriad RBM is a wholly owned subsidiary of Myriad Genetics, Inc.  Myriad RBM is a CLIA-certified reference laboratory.  Clinical researchers and healthcare providers receive reproducible, quantitative, multiplexed data for hundreds of proteins to advance drug development and patient care. The Company’s proprietary Multi Analyte Profiling (MAP) technology offers preclinical and clinical researchers with broad, cost-effective analyses of multiple proteins from a single, small sample volume.  MAP technology also supports Myriad RBM’s drive to develop companion diagnostics in areas of unmet medical needs.

More information about Myriad RBM can be found at www.myriadrbm.com.

About the Pulmonary Fibrosis Foundation

The Pulmonary Fibrosis Foundation mobilizes people and resources to provide access to high quality care and leads research for a cure so people with pulmonary fibrosis will live longer, healthier lives. The PFF collaborates with physicians, organizations, patients, and caregivers worldwide. The Pulmonary Fibrosis Foundation has a three-star rating from Charity Navigator and is a Better Business Bureau accredited charity. For more information, visit pulmonaryfibrosis.org or call 844TalkPFF (844.825.5733) or 312.587.9272 outside of the U.S.